This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barnett, J. A. Articles by Heimberger, A. B. Search for Related Content PubMed PubMed Citation Articles by Barnett, J. A. Articles by Heimberger, A. B.

Cytochrome P450 1B1 Expression in Glial Cell Tumors: An Immunotherapeutic Target

Authors' Affiliations: Departments of ¹ Neurosurgery, ² Pathology, and ³ Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; ⁴ Department of Pathology, The University of Aberdeen, Aberdeen, Scotland; and ⁵ Tulane University School of Medicine, New Orleans, Louisiana

Requests for reprints: Amy B. Heimberger, Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-2400; Fax: 713-794-4950; E-mail: aheimber{at}mdanderson.org.

Purpose: Among central nervous system malignancies, cytochrome P450 1B1 (CYP1B1) expression has only been characterized in medulloblastoma. An immunotherapeutic agent targeting this antigen was shown to safely stimulate a good immune response. To evaluate the viability of further research efforts targeting this antigen, we examined the expression of CYP1B1 in glial cell malignancies.

Experimental Design: We studied the frequency and extent of CYP1B1 expression by immunohistochemical analysis in 269 glial tumors (including all major pathologic types) on a tissue microarray. Results were categorized by percentage of cells stained and intensity of cytoplasmic staining within cells. Correlation of CYP1B1 expression with patient prognosis was evaluated by univariate and multivariate analyses.

Results: Overall, increased CYP1B1 expression in glial tumors was associated with decreased patient survival time (P < 0.0014 for both percentage and intensity of staining). A significant difference existed in percentage and intensity of staining between astrocytic and oligodendroglial tumors (P = 0.0002 and 0.0003, respectively), between grades of tumors (P < 0.0001 and 0.0079), and between pathologic types of tumors (P < 0.0001 and 0.0339). Positive CYP1B1 staining was seen in 81% of glioblastomas, 84% of anaplastic astrocytomas, 61% of oligodendrogliomas, and 67% of anaplastic oligodendrogliomas. Paradoxically, within specific tumor pathologies, there was a trend toward increased survival as CYP1B1 expression increased. However, in the multivariate analysis, this trend disappeared, and CYP1B1 expression seemed prognostically neutral.

Conclusion: CYP1B1 is frequently expressed in a variety of gliomas and could be used as a target for immunotherapy.

This article has been cited by other articles:

				F. Dutheil, S. Dauchy, M. Diry, V. Sazdovitch, O. Cloarec, L. Mellottee, I. Bieche, M. Ingelman-Sundberg, J.-P. Flinois, I. de Waziers, et al. Xenobiotic-Metabolizing Enzymes and Transporters in the Normal Human Brain: Regional and Cellular Mapping as a Basis for Putative Roles in Cerebral Function Drug Metab. Dispos., July 1, 2009; 37(7): 1528 - 1538. [Abstract] [Full Text] [PDF]

				W. R. Ware Nutrition and the Prevention and Treatment of Cancer: Association of Cytochrome P450 CYP1B1 With the Role of Fruit and Fruit Extracts Integr Cancer Ther, March 1, 2009; 8(1): 22 - 28. [Abstract] [PDF]

				M. Abou-Ghazal, D. S. Yang, W. Qiao, C. Reina-Ortiz, J. Wei, L.-Y. Kong, G. N. Fuller, N. Hiraoka, W. Priebe, R. Sawaya, et al. The Incidence, Correlation with Tumor-Infiltrating Inflammation, and Prognosis of Phosphorylated STAT3 Expression in Human Gliomas Clin. Cancer Res., December 15, 2008; 14(24): 8228 - 8235. [Abstract] [Full Text] [PDF]

				A. B. Heimberger, M. Abou-Ghazal, C. Reina-Ortiz, D. S. Yang, W. Sun, W. Qiao, N. Hiraoka, and G. N. Fuller Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas Clin. Cancer Res., August 15, 2008; 14(16): 5166 - 5172. [Abstract] [Full Text] [PDF]